Dhinesh Selvaraju: A Step Closer to the ‘Ideal Anticoagulant’?
Dhinesh Selvaraju, Clinical Research Assistant at Yuva Intern by Henry Harvin, shared a post on LinkedIn:
“A Step Closer to the ‘Ideal Anticoagulant’?
A significant advancement in thrombosis research is emerging from recent clinical evidence.
Bayer has reported encouraging Phase III results for its investigational oral Factor XIa inhibitor, Asundexian, evaluated in the OCEANIC-STROKE trial (2026) involving over 12,000 patients.
Key findings:
- Approximately 26% reduction in recurrent stroke risk
- No significant increase in major bleeding events
Why this matters ?
Despite their proven efficacy, current anticoagulants (DOACs, warfarin) are inherently limited by the risk of bleeding complications, often creating a therapeutic trade-off.
Asundexian introduces a novel mechanism:
- Selective inhibition of Factor XIa (intrinsic coagulation pathway)
- Targeting pathological thrombosis while preserving physiological hemostasis
Clinical significance:
- Reinforces the potential of Factor XI inhibition as a safer anticoagulation strategy
- Represents a promising shift in secondary stroke prevention
- Addresses a long-standing clinical challenge: Can thrombosis be prevented without increasing bleeding risk?
A paradigm shift in hemostasis:
This development reflects a broader transition in anticoagulant therapy:
From broad-spectrum anticoagulation to pathway-specific precision targeting
If validated through ongoing regulatory review, asundexian could redefine clinical practice in cerebrovascular risk management and set a new benchmark for next-generation anticoagulants.”
Stay updated with Hemostasis Today.
-
Jun 25, 2026, 19:32Javier M. Floren: A Blood Clot Is One of the Most Impressive Examples of Teamwork You’ll Ever See
-
Jun 25, 2026, 19:31Marcin Krzysztof Maniak: Linking Tissue Mechanics to Inflammation in Health and Disease
-
Jun 25, 2026, 19:29Deepak Rawat: A Diagnosis Like Immune Thrombocytopenia Changes Your Perspective
-
Jun 25, 2026, 19:27Srikanth R.: Don’t Ignore Your Health While Chasing Success
-
Jun 25, 2026, 19:27Jamie Nash: Delighted to Receive the BBTS Race and Sanger Award 2026
-
Jun 25, 2026, 15:56Wolfgang Miesbach: Building the Future of Gene Therapy – From Centre Readiness to Long-Term Patient Care
-
Jun 25, 2026, 15:46Amber Yates: Making a Meaningful Difference for People Living with Sickle Cell Disease
-
Jun 25, 2026, 15:43Nancy Cavey: Navigating Disability Benefits for Patients with Immune Thrombocytopenia
-
Jun 25, 2026, 15:28Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy